Traws Pharma products

Rigosertib is a small molecule that inhibits multiple cellular signaling pathways driving cancer cell growth while having little effect on normal cells. In contrast to many kinase inhibitors, rigosertib does not interact at the ATP binding site, but acts via allosteric inhibition. Rigosertib has the potential to affect three critical pathways for cancer cell proliferation and survival: the RAS/RAF/MEK/ERK, the PI3K/AKT and the PLK1 pathways. In addition, rigosertib may be a potent immunomodulator via the stimulation of neoantigen expression resulting in attraction of immune cells into the tumor microenvironment and thus making the tumor more susceptible to immunotherapy.

Narazaciclib (ON 123300) is a multi-kinase inhibitor targeting CDK 4/6 and additional kinases involved in tumor genesis, which the Company believes presents an innovative approach to treating advanced cancers including HR+ HER2- metastatic breast cancer that is, or has become, resistant to commercial CDK 4/6 inhibitors. Beyond metastatic breast cancer, the Company believes that  narazaciclib (ON 123300) may also present an innovative approach to treating other cancers including mantle cell lymphoma, multiple myeloma, advanced colorectal cancer, hepatocellular carcinoma and inoperable glioblastoma.